( NASDAQ-NMS:ISIS )

News from isis pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 18, 2015, 09:30 ET Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc.  Ionis...


Dec 18, 2015, 09:30 ET Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc.  Ionis...


Dec 17, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating...


Dec 17, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating...


Dec 11, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx...


Dec 11, 2015, 07:00 ET Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx...


Nov 10, 2015, 07:00 ET Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.8 million milestone payment from Biogen related to the...


Nov 09, 2015, 07:00 ET Isis Reports Financial Results and Highlights for Third Quarter 2015

 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported consolidated financial results for the third quarter of 2015 and highlighted...


Nov 08, 2015, 10:30 ET Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a Phase 2 study of...


Nov 06, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...


Nov 05, 2015, 07:00 ET Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to...


Nov 04, 2015, 07:00 ET Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American Heart Association Scientific Sessions

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Sunday, November 8 at 1:00 p.m. Eastern Time to...


Nov 03, 2015, 06:00 ET Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive preliminary results from an ongoing investigator sponsored, open-label...


Sep 11, 2015, 07:00 ET Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its collaboration with AstraZeneca to discover and develop antisense drugs for...


Sep 03, 2015, 07:00 ET Isis Pharmaceuticals to Present at Upcoming Investor Conferences

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...


Aug 04, 2015, 09:00 ET Isis Reports Financial Results And Highlights For Second Quarter 2015

 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported net income of $35.6 million and $18.9 million for the three and six months ended June...


Aug 03, 2015, 17:00 ET Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia

Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with...


Aug 03, 2015, 02:00 ET AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense...


Jun 30, 2015, 07:00 ET Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:   Corporate presentation at its 2015 Annual...


Jun 29, 2015, 14:41 ET ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has been added to the Russell 1000 Index, effective June 26, 2015. The...


Jun 22, 2015, 07:00 ET Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the...


Jun 16, 2015, 07:00 ET Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general...


Jun 11, 2015, 07:00 ET Isis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants...


Jun 10, 2015, 17:30 ET Isis Pharmaceuticals to Host Webcast to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Thursday, June 11 at 8:30 a.m. Eastern Time to...


Jun 05, 2015, 07:00 ET Isis Pharmaceuticals' License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize...